Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Achillion Strengthens Clinical Team, Readies HCV Nuc For Clinical Development

This article was originally published in The Pink Sheet Daily

Executive Summary

CSO Milind Deshpande will succeed Michael Kishbauch as CEO, while two HCV veterans from other companies will strengthen Achillion’s clinical development team. Meanwhile, the virology firm expects to file an IND for a nucleoside polymerase inhibitor later this year; only two antivirals from that class currently are in clinical development in HCV.

You may also be interested in...



Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”

In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.

Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity

Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.

US FDA’s New Drug Median Review Time Held Steady At Eight Months In 2021

The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel